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The aim of this study was to examine the eﬀect of toki-shakuyaku-san (TSS) on mild cognitive impairment (MCI) and Alzheimer’s
disease (AD) using single-photon emission computed tomography (SPECT). All subjects were administered TSS (7.5g/day) for
eight weeks. SPECT and evaluations using the Mini Mental State Examination (MMSE), Neuropsychiatric Inventory, and Physical
Self-Maintenance Scale were performed before and after treatment with TSS. Three patients with MCI and ﬁve patients with AD
completed the study. No adverse events occurred during the study period. After treatment with TSS, regional cerebral blood ﬂow
(rCBF)intheposteriorcingulatewassigniﬁcantlyhigherthanthatbeforetreatment.Nobrainregionshowedasigniﬁcantdecrease
inrCBF.TSStreatmentalsotendedtoimprovethescorefororientationtoplaceontheMMSE.TheseresultssuggestthatTSScould
be useful for treatment of MCI and AD.
1.Introduction
Cholinesterase inhibitors (ChEIs) and memantine, an N-
methyl-D-aspartate antagonist, are commonly used in treat-
ment of Alzheimer’s disease (AD). These drugs slow the
progression of the disease and improve cognition, function,
and behavior impairment but often have to be discontinued
because of adverse events [1, 2]. There are no approved
drugs for treatment of mild cognitive impairment (MCI).
A systematic review showed that ChEIs were ineﬀective in
preventingprogressionofMCItoADorimprovingcognitive
functions and led to adverse events [3].
There has been a recent increase in the use of traditional
herbal medicine for treatment of dementia. Yokukan-san has
been shown to improve behavioral and psychological symp-
toms of dementia (BPSD) [4, 5], hachimi-jio-gan improved
cognitive function and activity of daily living (ADL) in AD
[6], and choto-san was eﬀective for patients with vascular
dementia [7, 8]. Moreover, combination treatment with
kami-untan-to and donepezil improved cognitive function
and increased regional cerebral blood ﬂow (rCBF) in the
bilateral frontal lobes [9].
Toki-shakuyaku-san(TSS)ismainlyusedforgynecologic
disorders but has also been used for treatment of cognitive
impairment based on accumulated evidence of its neuroac-
tive and neuroprotective eﬀects. TSS activates cholinergic
[10–14] and monoaminergic [12, 13, 15] neurons and has a
protective eﬀect on amyloid β [16, 17], an antioxidant eﬀect
[18, 19], and an antiapoptosis action [12]. Several clinical
studies have also suggested that TSS improves cognitive
impairment in dementia, MCI, and poststroke patients [20–
22]. Brain imaging may be useful to examine the eﬀects of
TSS. Therefore, the aim of this study was to identify the
eﬀects of TSS in patients with MCI and AD using single-
photon emission computed tomography (SPECT).2 Evidence-Based Complementary and Alternative Medicine
2. Methods
2.1. Subjects. The subjects were 13 patients treated at the
Center for Diagnosis of Dementia at the Kyoto Prefectural
University of Medicine. Four patients were diagnosed with
MCI and 9 with AD, based on Petersen et al. [23] and the
National Institute of Neurological and Communicative Dis-
ease and Stroke-Alzheimer’s Disease and Related Disorders
Association (NINCDS-ADRDA) criteria for probable AD
[24]. We excluded patients with a signiﬁcant history of psy-
chiatric or neurological disorders (other than MCI and AD),
including stroke, head injury, epilepsy, psychiatric disorders,
alcohol abuse, or a serious medical condition. Participants
had not been prescribed ChEIs or memantine since our
center examines patients who have not been diagnosed with
dementia. This study was approved by the Ethics Committee
of the Kyoto Prefectural University of Medicine. Informed
consent was obtained from all of the patients.
2.2. Study Protocol. Subjects were treated with TSS given
as a daily dose of 7.5g of powder for eight weeks. During
this period, new medications were not introduced. TSS is
registered in the Pharmacopoeia of Japan as Kampo Medi-
cine TJ-23. The TSS used in the study was provided by Tsu-
mura (Tokyo, Japan) and was prepared from the extract of
a mixture of dried plants: 4.0g Paeoniae radix, 4.0g At-
ractylodis lanceae rhizoma, 4.0g Alismatis rhizoma, 4.0g
Hoelen, 3.0g Cnidii rhizome, and 3.0g Angelicae radix. All
subjects underwent magnetic resonance imaging (MRI) or
computed tomography (CT) before treatment. SPECT was
performed before and after treatment.
Cognitive impairment was evaluated using the Mini
Mental State Examination (MMSE) [25] before and after the
study period. The MMSE has 11 subscales including orien-
tation to time, orientation to place, registration, attention,
recall, naming, repetition, auditory comprehension/com-
mand, reading comprehension, sentence construction, and
constructional praxis. BPSD were evaluated before and aft-
er the study period using the Neuropsychiatric Inventory
(NPI) [26]. The NPI is a caregiver-based clinical instrument
that evaluates 10 domains of neuropsychiatric symptoms in
dementia: delusions, hallucinations, agitation, depression,
anxiety, euphoria, apathy, disinhibition, irritability, and
aberrant motor behavior. The frequency score ranges from 0
to 4 points, and the severity score ranges from 0 to 3 points.
The NPI score for each subscale is created by multiplying
the frequency and severity scores, with a maximum score
of 12. Therefore, the NPI total score ranges from 0 to 120.
Higher scores denote a greater severity of a symptom. ADL
before and after the study period were evaluated using the
Physical Self-Maintenance Scale (PSMS) [27], which consists
of 6 items related to physical activities: toileting, feeding,
dressing, grooming, ambulating, and bathing. A lower total
score indicates greater impairment of ADL.
2.3. Image Acquisition and Analysis. Brain perfusion SPECT
was performed by intravenous injection of 185MBq of
N-isopropyl-p-[123I]iodoamphetamine (I-123-IMP) (Nihon
Mediphysics, Hyogo, Japan) in subjects seated at rest with
their eyes open. SPECT imaging commenced 22min after
the injection and continued for 16min. A triple-head
gamma camera (Prism Irix, Picker International, Cleveland,
OH, USA) and a low-energy, high-resolution, and parallel
collimator were used. Projection data from each camera were
obtained in a128×128 formatfor 40angles of 1201 at 8s per
a n g l e( v o x e ls i z e :2×2 ×2mm).
Image analysis was performed using Statistical Paramet-
ric Mapping (SPM) 8 (Wellcome Department of Cognitive
Neurology, University College, London, UK) in Matlab 7.5
(Mathworks Inv., Sherborn, MA, USA). After conﬁrmation
of no signiﬁcant artifacts due to atrophy using MRI or CT
scans, all SPECT images were anatomically normalized using
the I-123-IMP template (Fujiﬁlm RI Pharma, Tokyo, Japan)
matched to the Montreal Neurological Institute (MNI) tem-
plate. The normalized images were smoothed using a 12-mm
full-width half-maximum (FWHM) isotropic Gaussian ker-
nel. To examine regional diﬀerences, the images were scaled
t oam e a ng l o b a lc e r e b r a lb l o o dﬂ o wo f5 0m L / 1 0 0g / m i n .
2.4. Statistical Analysis. A Wilcoxon signed rank test was
used to analyze the changes in MMSE, NPI, and PSMS
scores. Data were analyzed using SPSS 12.0 J for Windows
(SPSS Inc., Chicago, IL, USA). P<0.05 was considered
statistically signiﬁcant. A paired t-test was performed to
determine whether TSS aﬀected rCBF in patients with MCI
and AD. The X, Y,a n dZ coordinates provided by SPM
approximate the MNI brain space. The statistical thresholds
were set to a family-wise error (FWE)-corrected P value of
0.05 at the voxel level.
3. Results
3.1. Subject Characteristics. Eight of the 13 subjects com-
pleted the study. Five were discontinued because of poor
compliance (n = 3), a move to another area (n = 1),
and refusal to continue (n = 1). None of the subjects had
adverse events. The characteristics of the 8 subjects who
completed the study are shown in Table 1.S i xh a dn o tb e e n
prescribed with a psychoactive drug, 1 had taken risperidone
(1mg/day), and 1 had taken rilmazafone (0.5mg/day) before
the start of the study. Both subjects continued to take these
drugs during the study.
3.2. Changes in MMSE, NPI, and PSMS Scores. Changes in
MMSE, NPI, and PSMS scores are shown in Table 2.A t
baseline, cognitive impairment and BPSD were mild, and
ADL was high. Scores for the MMSE, NPI total, and PSMS
did not change signiﬁcantly after TSS treatment. Among the
MMSE subscales, the score for orientation to place showed
at e n d e n c yt oi m p r o v e( P = 0.025), but the change was
not signiﬁcant using a Bonferroni correction (P = 0.025 >
0.05/11) (Table 3).
3.3. Paired t-Test Using SPM. The paired t-test showed
a signiﬁcant increase in rCBF in the posterior cingulate
after TSS treatment compared to before treatment (Table 4).Evidence-Based Complementary and Alternative Medicine 3
Table 1: Clinical characteristics of subjects who completed the
study.
Item Value
Sex, M/F 3/5
Handedness, R/L 8/0
Age, y.o. 77.8 ± 4.9
Diagnosis, MCI/AD 3/5
Age at onset, y.o. 76.3 ± 4.3
Duration of illness, years 1.6 ±1.6
Education, years 12.0 ± 1.7
AD: Alzheimer’s disease; F: female; L: left; M: male; MCI: mild cognitive
impairment; R: right; SD: standard deviation; y.o.: years old.
Values are shown as a number ratio or as the mean ± SD.
Table 2: Changes in MMSE, NPI and PSMS scores from before to
after TSS treatment for 8 weeks.
Baseline
mean ± SD
8w e e k s
mean ± SD P value
MMSE 23.4 ±3.62 3 .9 ±3.8 0.279
NPI total score 5.5 ±5.93 .9 ±4.6 0.180
PSMS 5.9 ±0.45 .4 ±1.4 0.414
MMSE: Mini Mental State Examination; NPI: Neuropsychiatric Inventory;
PSMS: Physical Self-Maintenance Scale; SD: standard deviation.
Table 3:ChangesinMMSEsubscalescoresfrombeforetoafterTSS
treatment for 8 weeks.
Baseline
mean ± SD
8w e e k s
mean ± SD P value
Orientation to time 3.5 ±1.63 .1 ±2.1 0.414
Orientation to place 3.9 ±0.44 .5 ±0.5 0.025
Registration 3.0 ±0.03 .0 ±0.0 1.000
Attention 3.5 ±1.63 .4 ±1.6 0.655
Recall 1.0 ±1.21 .0 ±0.9 0.891
Naming 2.0 ±0.02 .0 ±0.0 1.000
Repetition 0.9 ±0.41 .0 ±0.0 0.317
Auditory
comprehension/command 2.8 ±0.53 .0 ±0.0 0.157
Reading comprehension 1.0 ±0.01 .0 ±0.0 1.000
Sentence construction 1.0 ±0.01 .0 ±0.0 1.000
Constructional praxis 0.9 ±0.40 .9 ±0.4 1.000
MMSE: Mini Mental State Examination; SD: standard deviation.
When the statistical thresholds were set to an uncorrected P
valueof0.001atthevoxellevelandacorrectedP valueof0.05
at the cluster level, the posterior cingulate was the only brain
region that showed a signiﬁcant increase in rCBF (Figure 1).
No brain region showed a signiﬁcant decrease in rCBF.
4. Discussion
Inthisstudy,rCBFintheposteriorcingulatewassigniﬁcantly
increased after eight weeks of treatment with TSS. The
MMSE, NPI total, and PSMS scores did not worsen and
adverseeventsdidnotoccurduringthetreatment.Moreover,
TSS treatment tended to improve the score for orientation to
place on the MMSE.
Some clinical studies have demonstrated improvement
in cognitive impairment by TSS in dementia and poststroke
patients. Inanaga et al. reported improvement in orientation
to time and place, spontaneous activity, emotional lability,
and motivation in 80 dementia patients (40 with vascular
dementia, 38 with AD, and 2 with mixed dementia) after
12 weeks of TSS treatment [20], while Goto et al. demon-
strated that TSS is eﬀective in suppressing impairment of
visuospatial perception and the lower limbs in poststroke
patients [22]. In our subjects, orientation to place tended
to improve while other cognitive impairments and BPSD
were unchanged. These ﬁndings are partly consistent with
previous studies and suggest that TSS might be particularly
eﬀective for improvement of spatial perception.
TSS treatment in this study was associated with a change
in rCBF in the posterior cingulate. This brain region plays
an important role in many cognitive functions, including
visuospatial orientation, topokinesis, navigation of the body
in space, self reﬂection, autobiographical memory, and
assessment of objects in space in terms of ﬁrst-person ori-
entation [28]. Connections between the posterior cingulate
and the parahippocampus are likely to play a major role
in memory-related functions [29], and these connections
may be disturbed in MCI and AD [30, 31]. Moreover,
hypofunction in the posterior cingulate is associated with
visuoperceptual deﬁcits in MCI and AD [32], as well as
disorientation to time and place in AD [33]. In this study,
TSS increased rCBF in the posterior cingulate and improved
orientation to place based on the MMSE. Therefore, TSS
might be useful for treatment of cognitive impairment
associated with the posterior cingulate.
Previous studies have shown that donepezil increases
or maintains rCBF, mainly in the frontal lobes [34–37]. In
contrast, in this study, TSS increased rCBF in the posterior
cingulate. In addition to the cholinergic eﬀect, TSS also has
monoaminergic, antiamyloid, antioxidant and antiapoptosis
eﬀects [10–19]. Collectively, these results suggest that TSS
has diﬀerent eﬀects on cognitive impairment compared to
thoseofdonepezil.Therefore,combiningTSSwithdonepezil
might have an additional beneﬁt in treatment of MCI and
AD.
The study has several limitations, since it was performed
with an open label design with no control group, the
observation period was short, and the sample size was small.
These limitations may reduce the strength of the results, but
the ﬁndings were partly consistent with previous studies.
Moreover, to our knowledge, this is the ﬁrst study to demon-
strate an eﬀect of TSS on rCBF in patients with MCI and AD.
5. Conclusions
Treatment with TSS signiﬁcantly increased rCBF in the pos-
terior cingulate and tended to improve orientation to place
in MCI and AD patients. Therefore, TSS might be useful for
treatment of MCI and AD. Moreover, since the eﬀects of TSS
on rCBF may diﬀer from those of donepezil, combination4 Evidence-Based Complementary and Alternative Medicine
Table 4: Results of paired t-tests.
Brain area
MNI coordinates at the center of the cluster Z value at the local
maximum
Voxel P value
(corrected)
Cluster
size
Cluster P value
(corrected) XYZ
Posterior cingulate 2 −32 40 5.66 0.002 6 <0.001
4 −24 44 5.08 0.039 1 0.015
25
20
15
10
5
0
Figure 1: Regions showing a signiﬁcant increase in rCBF after TSS treatment. The statistical thresholds were set to an uncorrected P value
of 0.001 at the voxel level and to a corrected P value of 0.05 at the cluster level.
therapy of TSS and donepezil might be particularly eﬀective.
A study in a large number of MCI and AD patients is needed
to conﬁrm the eﬀects of TSS.
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